Stay Connected. Manage Your Care.
Access your health information anytime and anywhere, at home or on the go, with MyHealth.
- Message your clinic
- View your lab results
- Schedule your next appointment
- Pay your bill
The MyHealth mobile app from Stanford Health Care puts all your health information at your fingertips and makes managing your health care simple and quick.
Guest Services
24/7
We are available to assist you
whenever you need it. Give us a call at
650-498-3333 or
PHYSICIAN HELPLINE
Have a question? We're here to help! Call 1-866-742-4811
Monday - Friday, 8 a.m. - 5 p.m.
REFER A PATIENT
Fax 650-320-9443
Track your patients' progress and communicate with Stanford providers conveniently and securely.
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.
This 2 arm study will compare the safety, tolerability and efficacy of aleglitazar and Actos
in patients with type 2 diabetes and symptomatic NYHA class II heart failure. Eligible
patients will be randomized to receive either aleglitazar, titrated to an individual maximum
tolerated dose up to 0.3mg p.o. daily, or Actos, titrated to an individual maximum tolerated
dose up to 45mg p.o. daily, in addition to prescribed diabetes therapy where applicable. The
anticipated time on study treatment is 3-12 months, and the target sample size is 100-500
individuals.